Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer-Reference-Cited by-同舟云学术

Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer

Published:2009-01 Issue:1 Volume:136 Page:187-195
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Farrell James J.,Elsaleh Hany,Garcia Miguel,Lai Raymond,Ammar Ali,Regine William F.,Abrams Ross,Benson A. Bowen,Macdonald John,Cass Carol E.,Dicker Adam P.,Mackey John R.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference35 articles.

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

2. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines;Mackey;Cancer Res,1998

3. Nucleoside transporters: molecular biology and implications for therapeutic development;Baldwin;Mol Med Today,1999

4. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters;Mackey;J Natl Cancer Inst,1999

5. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib);Ritzel;J Biol Chem,2001

Cited by 378 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming therapy resistance in pancreatic cancer: New insights and future directions;Biochemical Pharmacology;2024-11

2. Exploring novel dilazep derivatives as hENT1 inhibitors and potentially covalent molecular tools;Purinergic Signalling;2024-06-15

3. Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study);Cancer;2024-04-29

4. Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives;Expert Review of Clinical Pharmacology;2024-03-15

5. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness;Drug Resistance Updates;2024-03